Improving the Patient Experience With Longer Wear Infusion Sets Symposium Report

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

  • Kevin T. Nguyen
  • Nicole Y. Xu
  • Bruce A. Buckingham
  • Sarnath Chattaraj
  • Ohad Cohen
  • Lutz Heinemann
  • John Pickup
  • Svensson, Jannet
  • Robert A. Vigersky
  • Jenise C. Wong
  • Ralph Ziegler

Continuous subcutaneous insulin infusion (CSII) therapy is becoming increasingly popular. CSII provides convenient insulin delivery, precise dosing, easy adjustments for physical activity, stress, or illness, and integration with continuous glucose monitors in hybrid or other closed-loop systems. However, even as insulin pump hardware and software have advanced, technology for insulin infusion sets (IISs) has stayed relatively stagnant over time and is often referred to as the “Achilles heel” of CSII. To discuss barriers to insulin pump therapy and present information about advancements in, and results from clinical trials of extended wear IISs, Diabetes Technology Society virtually hosted the “Improving the Patient Experience with Longer Wear Infusion Sets Symposium” on December 1, 2021. The symposium featured experts in the field of IISs, including representatives from Steno Diabetes Center Copenhagen, University of California San Francisco, Stanford University, Medtronic Diabetes, and Science Consulting in Diabetes. The webinar’s seven speakers covered (1) advancements in insulin pump therapy, (2) efficacy of longer wear infusion sets, and (3) innovations to reduce plastics and insulin waste.

OriginalsprogEngelsk
TidsskriftJournal of Diabetes Science and Technology
Vol/bind16
Udgave nummer3
Sider (fra-til)775-782
Antal sider8
ISSN1932-2968
DOI
StatusUdgivet - 2022

Bibliografisk note

Funding Information:
The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: KTN and NYX have nothing relevant to disclose. BAB is on medical advisory boards for Convatec and Medtronic. BAB receives research support from the NIH, Medtronic, Insulet, Tandem, Beta Bionics, and Dexcom. SC is an employee of Medtronic. OC is an employee of Medtronic. LH is a consultant for a number of companies that are developing novel diagnostic and therapeutic options for diabetes treatment. He is a shareholder of the Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany. JP reports consultancy fees from Medtronic and BD. JS serves as an adviser to Medtronic and Novo Nordisk. She owns shares in Novo Nordisk and has received fees for speaking on behalf of Medtronic and Novo Nordisk. RAV is a full-time employee of Medtronic Diabetes. JCW has received research support from Dexcom, Inc and Tandem Diabetes Care. She is also a volunteer medical advisor and co-founder of Tidepool (for which she receives no compensation). RZ is on advisory boards of the following companies: Abbott, Lilly, Novo Nordisk and Roche. He has received speaking fees from Abbott, Dexcom, Glooko, Lilly, Menarini, Novo Nordisk and Roche.

Publisher Copyright:
© 2022 Diabetes Technology Society.

ID: 321544215